15,16-Dihydrotanshinone I inhibits the proliferation of MV4-11 by means of apoptosis via antagonizing FLT3-ITD/STAT5/Mcl-1 pathway

15,16-Dihydrotanshinone I inhibits the proliferation of MV4-11 by means of apoptosis via antagonizing FLT3-ITD/STAT5/Mcl-1 pathway

Till now, the medicines approved for acute myeloid leukemia with internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) display not ideal efficacy. This study aimed to evaluate the effects of 15,16-dihydrotanshinone I on FLT3-ITD acute myeloid leukemia cells. The inhibitory e...

Full description

Bibliographic Details
Main Authors:	Mansheng Luo, Yanmei Zeng, Xiaoling Deng
Format:	Article
Language:	English
Published:	Bangladesh Pharmacological Society 2023-01-01
Series:	Bangladesh Journal of Pharmacology
Subjects:	Acute myeloid leukemia Apoptosis 15,16-Dihydrotanshinone I FMS-like tyrosine kinase 3 Internal tandem duplication
Online Access:	https://www.banglajol.info/index.php/BJP/article/view/62376

Similar Items

15, 16-Dihydrotanshinone I Inhibits Hemangiomas through Inducing Pro-apoptotic and Anti-angiogenic Mechanisms in Vitro and in Vivo
by: Yihong Cai, et al.
Published: (2018-01-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-04-01)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
by: Jessica K. Altman, et al.
Published: (2021-02-01)

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
by: Amin Huang, et al.
Published: (2021-11-01)

Comparison of differences in blood laboratory results between acute promyelocytic leukemia and acute promyelocytic leukemia+FLT3-internal tandem duplication patients
by: Mehdi Mohammadi Kanesbi, et al.
Published: (2021-01-01)

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: <it>FLT3 ITD sustains high levels of DUSP6 expression</it>
by: Arora Deepika, et al.
Published: (2012-07-01)

Enhanced Bioavailability of Dihydrotanshinone I–Bovine Serum Albumin Nanoparticles for Stroke Therapy
by: Yanru Ren, et al.
Published: (2021-08-01)

Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells
by: Lorenzo Allegri, et al.
Published: (2021-07-01)

Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation
by: Shintaro Izumi, et al.
Published: (2020-09-01)

Biotransformation of triterpenoid ganoderic acids from exogenous diterpene dihydrotanshinone I in the cultures of Ganoderma sessile
by: Xinwei Wang, et al.
Published: (2023-07-01)

Dihydrotanshinone Triggers Porimin-Dependent Oncosis by ROS-Mediated Mitochondrial Dysfunction in Non-Small-Cell Lung Cancer
by: Dongjie Zhang, et al.
Published: (2023-07-01)

Dihydrotanshinone I inhibits hepatocellular carcinoma cells proliferation through DNA damage and EGFR pathway
by: Linjun Wang, et al.
Published: (2023-03-01)

Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia
by: Javier Bregante, et al.
Published: (2021-12-01)

Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells
by: Mengge Wang, et al.
Published: (2022-11-01)

FMS-LIKE TYROSINE KINASE (FLT3) GENE ITD MUTATION IN ACUTE MYELOID LEUKEMIA
by: Rajko Kusec, et al.
Published: (2004-12-01)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
by: Shano Naseem, et al.
Published: (2021-01-01)

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

Dihydrotanshinone I preconditions myocardium against ischemic injury via PKM2 glutathionylation sensitive to ROS
by: Xunxun Wu, et al.
Published: (2023-01-01)

Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations
by: Shaina N Porter, et al.
Published: (2016-11-01)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
by: Tobias R. Haage, et al.
Published: (2023-05-01)

TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity
by: Xiaoping Wang, et al.
Published: (2020-05-01)

FMS-like tyrosine kinase 3 internal tandem duplication mutation in patients with acute myeloid leukemia in Kurdistan region/Iraq
by: Sarween Sherzad Rasool, et al.
Published: (2023-01-01)

Evaluation of Cytogenetic Changes and FLT3 mutations in Patients with Acute Promyelocytic Leukemia
by: Marjan Yaghmaie, et al.
Published: (2010-09-01)

Evaluation of Cytogenetic Changes and FLT3 mutations in Patients with Acute Promyelocytic Leukemia
by: Marjan Yaghmaie, et al.
Published: (2010-07-01)

Dihydrotanshinone I Specifically Inhibits NLRP3 Inflammasome Activation and Protects Against Septic Shock In Vivo
by: Ziying Wei, et al.
Published: (2021-10-01)

Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia
by: Song Y, et al.
Published: (2021-03-01)

The Nrf2-inducers tanshinone I and dihydrotanshinone protect human skin cells and reconstructed human skin against solar simulated UV
by: Shasha Tao, et al.
Published: (2013-01-01)

Dihydrotanshinone I Attenuates Atherosclerosis in ApoE-deficient Mice: Role of NOX4/NF-κB Mediated Lectin-like Oxidized LDL Receptor-1 (LOX-1) of the Endothelium
by: Wenwen Zhao, et al.
Published: (2016-11-01)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
by: Riad El Fakih, et al.
Published: (2018-01-01)

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
by: Szymon Milnerowicz, et al.
Published: (2023-10-01)

Dihydrotanshinone I Inhibits the Lung Metastasis of Breast Cancer by Suppressing Neutrophil Extracellular Traps Formation
by: Huan Zhao, et al.
Published: (2022-12-01)

DihydrotanshinoneⅠ promotes apoptosis of human esophageal squamous cell carcinoma cell line EC9706
by: WANG Xiu-mei, WANG Kang-kang, CHEN Xiao-yan, LUO Jin-jian
Published: (2020-07-01)

Detection of FLT3-ITDMutation in Twenty ChildwithAcuteMyeloidLeukemia in One Iraqi Teaching Hospital
by: Ethar k. Dhahir, et al.
Published: (2012-07-01)

Assessing the Economic Feasibility of Short-Rotation Woody Crops in Florida
by: Matthew Langholtz, et al.
Published: (2007-07-01)

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia
by: Moo-Kon Song, et al.
Published: (2022-10-01)

Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine)
by: Pascal Kintz, et al.
Published: (2021-10-01)

FLT3 inhibitors in acute myeloid leukemia
by: Mei Wu, et al.
Published: (2018-12-01)

Cordoba and Jerez de la Frontera in the reign of Ferdinand and Isabella, 1474-1516
by: Edwards, J
Published: (1976)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
by: Ahmed M. Abbas, et al.
Published: (2018-07-01)

Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U−2 OS Cells through CD44 and Chemokine Signaling
by: Lanyan Fan, et al.
Published: (2022-06-01)